報價延遲最少15分鐘:2025/03/12 22:32 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
9.08 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.78/-3.18
|
|
企業價值
508.16M
|
| 資產負債 |
|
每股賬面淨值
10.09
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/03/12 22:32 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies. |